chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 0.33
Sex: U
Vaccine: HIBV
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report was received from a physician referring to an unknown number of patients of unknown gender and age. Pertinent medical history or concurrent conditions were not reported. Since 30-MAY-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB which had the lot # reported as N00236, expiration date 24-OCT-2019, lot # N000235, expiration date 26-OCT-2019, lot # N003536, expiration date 02-NOV-2019, for prophylaxis (dosage information and route were not informed). Information regarding concomitant medication was not provided. Additionally, it was reported that the lowest temperature was 32 degrees Fahrenheit and the highest was 54 degrees Fahrenheit for 49 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. This is one case from several cases from the same reporter. Follow-up information has been received from a physician on 16-OCT-2017 to an unknown number of patients of unknown gender and age. The patients' concomitant medications, pertinent medical history, drug reactions or allergies were not reported. Since 29-APR-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB (lot # M046140, expiration date 27-SEP-2019, dosage information and route were not provided) for prophylaxis. Additionally, it was reported that the lowest temperature was 47° degrees Fahrenheit and the highest was 49° degrees Fahrenheit for 16 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. Follow up information was received from the physician on 27-OCT-2017. This report refers to 4 month old patient. On 10-JUN-2017, the patient was vaccinated with improperly stored doses of PEDVAXHIB lot# N000235 with expiration date: 26-OCT-2019. This is one case from several cases from the same reporter. Sender's Comments: US-009507513-1709USA012770: US-009507513-1709USA012767: US-009507513-1709USA012768: US-009507513-1709USA012769: US-009507513-1709USA012765: US-009507513-1709USA012764: US-009507513-1709USA007325: US-009507513-1709USA012766.
Age: 0.83
Sex: U
Vaccine: HIBV
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report was received from a physician referring to an unknown number of patients of unknown gender and age. Pertinent medical history or concurrent conditions were not reported. Since 30-MAY-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB which had the lot # reported as N00236, expiration date 24-OCT-2019, lot # N000235, expiration date 26-OCT-2019, lot # N003536, expiration date 02-NOV-2019, for prophylaxis (dosage information and route were not informed). Information regarding concomitant medication was not provided. Additionally, it was reported that the lowest temperature was 32° degrees Fahrenheit and the highest was 54° degrees Fahrenheit for 49 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. This is one case from several cases from the same reporter. Follow-up information has been received from a physician on 16-OCT-2017 to an unknown number of patients of unknown gender and age. The patients' concomitant medications, pertinent medical history, drug reactions or allergies were not reported. Since 29-APR-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB (lot # M046140, expiration date 27-SEP-2019, dosage information and route were not provided) for prophylaxis. Additionally, it was reported that the lowest temperature was 47° degrees Fahrenheit and the highest was 49° degrees Fahrenheit for 16 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. Follow up information was received from the physician on 27-OCT-2017. This report refers to 10 month old patient. On 12-JUN-2017, the patient was vaccinated with improperly stored doses of PEDVAXHIB lot# N000235 with expiration date: 24-OCT-2019. This is one case from several cases from the same reporter. Sender's Comments: US-009507513-1709USA012770: US-009507513-1709USA012767: US-009507513-1709USA012768: US-009507513-1709USA012769: US-009507513-1709USA012765: US-009507513-1709USA012764: US-009507513-1709USA007325: US-009507513-1709USA012766.
Age: 1.75
Sex: F
Vaccine: FLU4
Symptoms: Decreased activity, Decreased appetite, Lymphadenopathy, Malaise, Poor quality sleep
Clinical narrative: Started with fever on 10/27, which lasted several days; maximal temperature 101.8 degrees. Sluggish/decreased activity, decreased appetite. Restless sleep. No respiratory symptoms, gastrointestinal symptoms (other than 2 episodes of vomiting a day apart, each time shortly after being given TYLENOL) and no rash. Child was evaluated on 10/31, a little sluggish but responding appropriately, mildly ill-appearing. Exam otherwise normal except for enlarged lymph nodes, to 1 cm in cervical region, and 4 to 5 mm in inguinal region.
Age: 1.75
Sex: F
Vaccine: FLU4
Symptoms: Pyrexia, Sluggishness, Vomiting
Clinical narrative: Started with fever on 10/27, which lasted several days; maximal temperature 101.8 degrees. Sluggish/decreased activity, decreased appetite. Restless sleep. No respiratory symptoms, gastrointestinal symptoms (other than 2 episodes of vomiting a day apart, each time shortly after being given TYLENOL) and no rash. Child was evaluated on 10/31, a little sluggish but responding appropriately, mildly ill-appearing. Exam otherwise normal except for enlarged lymph nodes, to 1 cm in cervical region, and 4 to 5 mm in inguinal region.
Age: 34.0
Sex: M
Vaccine: FLU4
Symptoms: Hypoaesthesia, Laboratory test normal, Muscle spasms, Myalgia, Swelling
Clinical narrative: Reaction started with muscle pain and spasm on right forearm. Then muscle spasm occurred throughout the body with "swelling". Pt reported all muscle spasms were very painful. Went to pcp on Monday, after injection on Friday morning, and received a prescription for Flexeril and Motrin. All lab work WNL except possibly "eosinophils" elevated. As of 10/13/2017 patient experienced numbness in his arms. On 10/27/17 patient states now numbness only present on finger tips. Plans to have consult with neurologist concerning the remaining symptom.
Age: 0.25
Sex: M
Vaccine: DTAPIPVHIB, HEP, PNC13
Symptoms: Dehydration, Diarrhoea, Hypophagia, Vomiting, Weight increased
Clinical narrative: Vomiting, poor oral intake, and mild dehydration within 24 hours. Vomiting continued x 3 days total, few loose diarrheal stools for 2 days after onset of diarrhea. Seen in ER after patient failed outpatient oral Pedialyte challenge. Repeated Pedialyte challenge and patient tolerated oral intake well. Sent home and improved over next 2 days. Seen back in PCP office 4 days after vaccines with weight gain of 7 oz in 4 days.
Age: 54.0
Sex: F
Vaccine: FLU4, PPV, TDAP
Symptoms: Axillary pain, Body temperature increased, Fatigue, Pain in extremity, Rash
Clinical narrative: Ran a temperature, low grade. Sore and tender on arm and under armpit. Oblong rash. Hot to touch. Right arm only. Felt fatigue following the next day.
Age: 54.0
Sex: F
Vaccine: FLU4, PPV, TDAP
Symptoms: Skin warm, Tenderness
Clinical narrative: Ran a temperature, low grade. Sore and tender on arm and under armpit. Oblong rash. Hot to touch. Right arm only. Felt fatigue following the next day.
Age: 1.0
Sex: F
Vaccine: HEP, HEPA, MMRV
Symptoms: Dehydration, Hypophagia, Oral disorder, Pyrexia, Rash
Clinical narrative: Child had fever for 3 days and emesis rash Decreased PO intake child was sent to Hospital report was sent to Dr office stating child had mild dehydration in the setting of varicella chicken pox mouth lesions.
Age: 1.0
Sex: F
Vaccine: HEP, HEPA, MMRV
Symptoms: Varicella post vaccine, Vomiting
Clinical narrative: Child had fever for 3 days and emesis rash Decreased PO intake child was sent to Hospital report was sent to Dr office stating child had mild dehydration in the setting of varicella chicken pox mouth lesions.
Age: 63.0
Sex: M
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: None known.
Age: 61.0
Sex: M
Vaccine: FLU3
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: None known.
Age: 14.0
Sex: F
Vaccine: HEP, HEPA, HPV9, IPV, MNQ, TDAP
Symptoms: Extra dose administered
Clinical narrative: I gave a second Tdap for a primary series instead of a Td. I also gave MENVEO at age 14 when she had had a previous unspecified meningitis immunization at age 11.
Age: 23.0
Sex: F
Vaccine: FLU4, PPV, TDAP
Symptoms: Injection site erythema, Pyrexia
Clinical narrative: Patient received Tdap and FLUZONE in the right deltoid on 10/24, then received PNEUMOVAX in the right deltoid on 10/25. They developed a fever on 10/16 (Tmax 39.5), and large (12 x 15 cm) area of erythema on the right deltoid on 10/27. They were treated with IV and PO diphenhydramine, and were discharged on 10/28 after resolution of fever and reduction in the erythematous area.
Age: 57.0
Sex: M
Vaccine: FLUC4
Symptoms: Pain in extremity
Clinical narrative: Sore arm.
Age: 11.0
Sex: M
Vaccine: FLU4
Symptoms: Rash
Clinical narrative: RASH TO RIGHT ARM AND UPPER BACK. GRANDMOTHER ADVISED TO GIVE HIM ORAL BENADRYL AND ORAL IBUPROFEN FOR ANY PAIN. ADVISED TO GO TO NEAREST ER IF ANY SIGNS OF ANAPHYLACTIC REACTION.
Age: 9.0
Sex: F
Vaccine: FLU4
Symptoms: Blood pressure increased, Dizziness, Dyspnoea, Rash erythematous, Rash generalised
Clinical narrative: This case was reported by a other health professional via call center representative and described the occurrence of difficulty breathing in a 9-year-old female patient who received FLULAVAL QUADRIVALENT (batch number PN75E, expiry date 31st May 2018). Previously administered products included flu vaccines. On 25th October 2017 01:23, the patient received FLULAVAL QUADRIVALENT (intramuscular) .5 ml. On 25th October 2017, less than a day after receiving FLULAVAL QUADRIVALENT, the patient experienced difficulty breathing (serious criteria life threatening), dizziness (serious criteria life threatening), increased blood pressure (serious criteria life threatening) and erythematous rash (serious criteria life threatening). On an unknown date, the outcome of the difficulty breathing, dizziness and erythematous rash were recovering/resolving and the outcome of the increased blood pressure was unknown. The reporter considered the difficulty breathing, dizziness, increased blood pressure and erythematous rash to be possibly related to FLULAVAL QUADRIVALENT. Additional details were reported as follows: The patient had been given flu vaccines in the past but this was the first time she had been given FLULAVAL QUADRIVALENT. Following administration of FLULAVAL QUADRIVALENT, the patient got down from the table and sat on the floor and told her mother she couldn't breathe. The patient then said she felt dizzy. She also had a  red  rash all over her body. The rash started to fade but the difficulty breathing lasted a little longer. All symptoms seemed to be resolving when she left the office. The reporter felt at the time the patient couldn't breathe, it was life threatening but now seems to be okay. The doctor took her blood pressure and said it was higher than normal but that was a good thing.
Age: 69.0
Sex: F
Vaccine: PPV
Symptoms: Peripheral swelling
Clinical narrative: Patient's arm started to swell a few hours after the vaccine was administered. It swelled significantly large. She came in that night to show the pharmacy staff. It was the upper arm that had swollen. Later, she said the lower part of her arm was swollen.
Age: 52.0
Sex: F
Vaccine: MMR
Symptoms: Eyelid oedema, Paraesthesia
Clinical narrative: Left eye puffy and swollen and tingling in her face. Took antihistamine last night and has improved today but still present.
Age: 14.0
Sex: F
Vaccine: FLU4
Symptoms: Rash
Clinical narrative: RASH RIGHT ARM AND UPPER BACK, GRANDMOTHER ADVISED TO GIVE ORAL BENADRYL AND ORAL IBUPROFEN AS NEEDED FOR PAIN. ADVISED TO GO TO NEAREST ER IF ANY SIGNS OF ANAPHYLACTIC REACTION.
Age: 80.0
Sex: F
Vaccine: PNC13
Symptoms: Decreased appetite, Headache, Heart rate increased, Injection site pain, Insomnia
Clinical narrative: Extreme pain in left arm from shoulder to elbow - underarm swollen - couldn't move arm - headache on left side of head only - rapid heartbeat, area hot, swollen - couldn't sleep - no appetite. Couldn't make myself get out of bed Oct. 31 a.m. Finally forced myself to get out and dressed and report to facility Immunization condition.
Age: 80.0
Sex: F
Vaccine: PNC13
Symptoms: Mobility decreased, Skin warm, Swelling
Clinical narrative: Extreme pain in left arm from shoulder to elbow - underarm swollen - couldn't move arm - headache on left side of head only - rapid heartbeat, area hot, swollen - couldn't sleep - no appetite. Couldn't make myself get out of bed Oct. 31 a.m. Finally forced myself to get out and dressed and report to facility Immunization condition.
Age: 66.0
Sex: M
Vaccine: FLU4
Symptoms: Erythema, Peripheral swelling
Clinical narrative: Patient presented to Outpatient Clinic 10/27/17 with significant arm swelling and erythema. Patient received the influenza vaccine on 9/29/17 per documentation. Patient was treated with a cold compress and instructed to follow up with clinic.
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pruritus, Injection site rash, Pain in extremity
Clinical narrative: PATIENT DEVELOPED RED ITCHY RASH SHORTLY AFTER GETTING ZOSTAVAX VACCINE. PATIENT CONTACTED THE PHARMACY ON 10/31 SAYING SHE STILL HAS A RED RASH AT THE SITE OF INJECTION (NOT ITCHY ANYMORE) AND THAT HER ARM IS SORE FROM HER SHOULDER TO HER WRIST. ADVISED PATIENT TO CONTACT HER PHYSICIAN.
Age: 63.0
Sex: F
Vaccine: FLU4
Symptoms: Blood pressure increased, Condition aggravated
Clinical narrative: Extremely elevated blood pressure.
Age: 1.08
Sex: F
Vaccine: VARCEL
Symptoms: Pyrexia, Rash
Clinical narrative: Symptoms started 10-27-2017 rash, fever.
Age: 4.0
Sex: M
Vaccine: DTAPIPV, MMRV
Symptoms: Borrelia test, Facial paralysis, Full blood count
Clinical narrative: RIGHT FACIAL NERVE PALSY (BELL'S PALSY). ED VISIT PM AFTER ONSET, MY OFFICE NEXT AM. SEEN BY NEURO IN ED, PREDNISONE GIVEN FOR 5 DAYS. ADVISED F/U IF PERSISTENT BEYOND 2 WEEKS.  PARENTS WANTED SOONER TRIP BACK TO NEURO AND PT APPT...BOTH SET UP.
Age: 3.0
Sex: F
Vaccine: FLU4
Symptoms: Dyskinesia, Fall, Head injury, Muscle spasms
Clinical narrative: PT FELL AND HIT FOREHEAD ON CLINIC FLOOR ABOUT 2-3 MINS AFTER VACCINE WAS ADMINISTERED. PT BEGAN TO HAVE A HAVE SPASMS AND JERKING IN ALL FOUR EXTREMITIES.
Age: 60.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Gait disturbance, Injection site swelling, Muscular weakness, Musculoskeletal pain
Clinical narrative: A few hours after patient received both vaccinations, she went out to dinner. At dinner, she had some wine and at the conclusion of the meal, her leg "just gave out" and she had trouble walking. For the next 4 days, her husband had to help her with walking as she had muscle weakness. In addition, she said there was swelling on her injection site and pain in her shoulder. She informed the pharmacy of this on the fourth day of the reaction, 10/30/17. The pharmacist advised to her seek prompt medical attention. We followed up with her the next day at which point she states that she chose not to visit a doctor because she is feeling much better. We recommended again for her to visit a doctor and she stated that she will bring up the matter with her neurologist at her next appointment on 11/7/17.
Age: 57.0
Sex: F
Vaccine: FLUX
Symptoms: Injection site erythema, Injection site oedema, Injection site swelling
Clinical narrative: ?? cellulitis, red, swollen from shot area to elbow, ?? fluid accumulation under skin. Rx with steroids -- improving.
Age: 53.0
Sex: F
Vaccine: FLU3
Symptoms: Hypoaesthesia, Injection site hypoaesthesia, Injection site paraesthesia, Paraesthesia
Clinical narrative: Employee experienced numbness and tingling from her neck down her left arm to her fingers.
Age: 14.0
Sex: M
Vaccine: MMRV
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: Patient came in on 10/16/2017 and received the MMRV vaccine. He is 14 years old and was not suppose to receive vaccine because the age limit is 12 months and 12 years old. Patient is fine, he is not having any rash or fever. Doctor spoke to mom yesterday about having abd pain, that is from the sickle cell disease.
Sex: U
Vaccine: VARCEL
Symptoms: Expired product administered, No adverse event
Clinical narrative: This spontaneous report was received from a nurse practitioner and refers to a patient of unknown age and gender. No information regarding the patient's medical history and concurrent conditions was provided. On 13-OCT-2017, the patient received an expired dose of VARIVAX lot # L035124, expiration date: 14-SEP-2017, one dose, subcutaneously, for prophylaxis. Concomitant therapies included sterile diluent (manufacturer unknown). No adverse effect was reported.
Sex: F
Vaccine: FLUX, PPV
Symptoms: Erythema, Injection site warmth, Pain
Clinical narrative: This spontaneous report was received from a pharmacist and refers to a 63-year-old female patient. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 24-AUG-2017, the patient was vaccinated with PNEUMOVAX 23 lot # N010105, expiration date: 15-NOV-2018, subcutaneously, to prevent from pneumonia. Concomitant therapies included influenza virus vaccine (unspecified). On 24-AUG-2017 (reported as "later that evening"), the patient experienced pain, redness and the injection site was hot to touch. The patient spoke to a medical personnel and she was treated with BENADRYL (reported as "Benedryl") and ice packs to the injection site. On an unknown date in 2017, the patient recovered from all of the events. The causal relationship between the events and PNEUMOVAX 23 was not provided.
Age: 64.0
Sex: F
Vaccine: PPV, TD
Symptoms: Administration site inflammation, Administration site pain, Injection site erythema, Injection site pain
Clinical narrative: This spontaneous report as received from an other health professional via MassBiologic refers to a 64 year old female patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 17-JUL-2017 at 13:15, the patient was vaccinated with PNEUMOVAX 23 in the right deltoid, lot # N011491, expiration date 04-NOV-2018 (dose and route of administration were not reported). Other suspect therapies included tuberculin purified protein derivative, lot# C5039AA, for tuberculosis test (dose, concentration, route of administration, expiration date were not reported) and diphtheria toxoid, tetanus toxoid dose 0.5 ml, injection, suspension, intramuscularly, in right deltoid, lot nr A096A (expiration date was not reported). On 20-JUL-2017, the patient experienced tenderness, soreness, inflammation, and redness around the site of administration (right deltoid). Action taken with tuberculin purified protein derivative was not reported. The outcome of the events was unknown. The causality assessment was not provided.
Sex: U
Vaccine: PPV
Symptoms: Inappropriate schedule of drug administration, No adverse event
Clinical narrative: This spontaneous report was received from a medical assistant referring to a 74 year old patient of unknown age. The patient's pertinent medical history, concurrent conditions or concomitant medications were not reported. On 14-SEP-2011, the patient was vaccinated with 1 dose of PNEUMOVAX 23 intramuscularly (lot# and frequency were unspecified) for prophylaxis. Then, the patient received a dose of PREVNAR 13 on 05-JUL-2016. The patient then received another dose of PNEUMOVAX 23 intramuscularly, lot# N010105 (expiration date: 15-NOV-2018) for prophylaxis on 16-OCT-2017. No adverse effects were reported.
Sex: U
Vaccine: VARZOS
Symptoms: Expired product administered, No adverse event
Clinical narrative: This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not provided. On 07-OCT-2017, the patient was vaccinated with an expired dose of ZOSTAVAX (lot # M041510, expiration date 27-JUL-2017), subcutaneously (strength and dose were not provided) which was reconstituted with sterile diluent for prophylaxis. No adverse effects were reported. No product quality complaint was involved.
Age: 5.0
Sex: F
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report has been received from a Medical Assistant referring to a 5 year old female patient. No information was provided regarding the patient's medical history, concurrent conditions, drug, allergy history or concomitant medications. On 05-OCT-2017, the patient was vaccinated with an improperly stored dose of PROQUAD first dose, lot # N014950, intramuscularly in the left deltoid (strength, and expiration date were not provided) for prophylaxis. Concomitant therapies included sterile diluent (STERILE MRK). The doses of PROQUAD were exposed to a temperature excursion of 6°Fahrenheit (°F) to 14°F (6.62°F) during a time frame of 4 hours, which was detected by the data logger. There was no previous temperature excursion. No adverse effects were reported
Age: 59.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Injection site cellulitis
Clinical narrative: Information has been received from a registered nurse reporting on a 59 year old female patient. The patient's concurrent conditions include congestive heart failure, Hodgkin's disease, hypothyroidism and allergy to sulfa. The patient's concomitant medication included acyclovir (ZOVIRAX), bupropion hydrochloride (WELLBUTRIN), cyclobenzaprine hydrochloride (FLEXERIL) acetaminophen, hydrocodone bitartrate (NORCO), levothyroxine sodium (SYNTHROID) and meloxicam. There was noinformation about the patient's medical history. On 06-OCT-2017, the patient received an unspecified dose of PNEUMOVAX 23 lot # N014946, epiration date 01-FEB-2019, intramuscular, in the leftoid area (unspecified arm) for prophylaxis. On the same date, the patient received on the same area a dose of FLUZONE (dose, route of administration, lot number and expiration date were not reported). On 08-OCT-2017, the patient developed "cellulitis like symptom" from the area below the injection site down to the elbow. The nurse indicated that the patient sought medical attention and received treatment for the adverse event. No lab diagnostics/studies were performed. The outcome of the event cellulitis and its causal relationship with PNEUMOVAX 23 or FLUZONE were not reported. Upon internal review, cellulitis was considered to be a medically signifcicant event.
Age: 1.08
Sex: F
Vaccine: MMR, VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 14-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 19-SEP-2017, the patient was vaccinated with improperly stored VARIVAX (lot # M039317; expiry date: 20-SEP-2018) and M-M-R II (lot # M034387; expiry date: 19-JUL-2018) for prophylaxis. The dose of VARIVAX was reconstituted with properly stored sterile diluent (MERCK). The doses of VARIVAX were exposed to temperature range between 6° Fahrenheit (F) to 14°F during a time frame of 1 hour 20 minutes. There were no previous temperature excursions. Digital data logger was involved. No adverse effects were reported. Product Quality Complaint (PQC) was not involved. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666 US-009507513-1710USA014650: Original Case: 1710USA014649 US-009507513-1710USA014651: Original Case: 1710USA014649.
Age: 1.0
Sex: F
Vaccine: MMR, VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 13-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 11-SEP-2017, the patient was vaccinated with improperly stored VARIVAX (lot # M039317; expiry date: 20-SEP-2018) and M-M-R II (lot # M034387; expiry date: 19-JUL-2018) for prophylaxis. The dose of VARIVAX was reconstituted with properly stored sterile diluent (MERCK). The doses of VARIVAX were exposed to temperature range between 6° Fahrenheit (F) to 14°F during a time frame of 1 hour 20 minutes. There were no previous temperature excursions. Digital data logger was involved. No adverse effects were reported. Product Quality Complaint (PQC) was not involved. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014649: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649.
Age: 1.0
Sex: F
Vaccine: MMR, VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 13-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 08-SEP-2017, the patient was vaccinated with improperly stored VARIVAX (lot # M039317; expiry date: 20-SEP-2018) and M-M-R II (lot # M034387; expiry date: 19-JUL-2018) for prophylaxis. The dose of VARIVAX was reconstituted with properly stored sterile diluent (MERCK). The doses of VARIVAX were exposed to temperature range between 6° Fahrenheit (F) to 14°F during a time frame of 1 hour 20 minutes. There were no previous temperature excursions. Digital data logger was involved. No adverse effects were reported. Product Quality Complaint (PQC) was not involved. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Age: 1.0
Sex: F
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report as received from a registered nurse via medical assistant and refers to a 13-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 11-SEP-2017, the patient was vaccinated with improperly stored VARIVAX (lot # M039317; expiry date: 20-SEP-2018) for prophylaxis. The dose of VARIVAX was reconstituted with properly stored sterile diluent (MERCK). The doses of VARIVAX were exposed to temperature ranges between 6° Fahrenheit (F) to 14°F during a time frame of 1 hour 20 minutes. There were no previous temperature excursions. Digital data logger was involved. No adverse effects were reported. Product Quality Complaint (PQC) was not involved. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1710USA014649: Original Case: 1709USA008666: US-009507513-1710USA014650: US-009507513-1710USA014651: US-009507513-1709USA008666: Original Case: 1709USA008666.
Age: 2.0
Sex: M
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 2-year-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 03-OCT-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458:  US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Age: 1.67
Sex: M
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 21-month-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 29-SEP-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Age: 1.25
Sex: F
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 16-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 19-SEP-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Age: 1.17
Sex: F
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 14-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 29-SEP-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Age: 1.0
Sex: M
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 13-month-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 18-SEP-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Age: 1.08
Sex: M
Vaccine: MMR
Symptoms: Product storage error
Clinical narrative: This spontaneous report was received from a registered nurse via medical assistant and refers to a 13-month-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 16-OCT-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.